Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - amifampridine
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mpeea75696c0638bfef12b52e191d0d8ce
identifier: http://ema.europa.eu/identifier
/EU/1/22/1646/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Amifampridine SERB 10 mg tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-eea75696c0638bfef12b52e191d0d8ce
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/22/1646/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - amifampridine
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Amifampridine SERB contains the active substance amifampridine.
Amifampridine SERB is used to treat symptoms of a disease of the nerves and the muscles called Lambert-Eaton myasthenic syndrome or LEMS in adults. This disease is a disorder affecting the transmission of nerve impulses to muscles, resulting in muscle weakness. It can be associated with certain tumour types (paraneoplastic form of LEMS) or in the absence of these tumours (non-paraneoplastic form of LEMS).
In patients suffering from this disease, a chemical substance called acetylcholine, which communicates nerve impulses to muscles is not released normally and the muscle doesn't receive some or all of the nerve's signals.
Amifampridine SERB works by increasing the release of acetylcholine and helps the muscle to receive the nerve signals.
Do not take Amifampridine SERB If you are allergic to amifampridine, or any of the other ingredients of this medicine (listed in section 6). If you have uncontrolled asthma If you are epileptic Together with medicines that may change the electrical activity of your heart (QT-interval prolongation - detectable in the electrocardiogram), such as: Sultropride (a medicine prescribed to treat certain behavioural disorders in adults),
Antiarrhythmic medicine (e.g., disopyramide)
Medicines to treat digestive problems (e.g., cisapride, domperidone) Medicines to treat infections - antibiotics (e.g., rifampicin) and antifungals (e.g., ketoconazole) Together with medicines with a therapeutic dose close to the maximum safe dose If you were born with heart problems (congenital QT syndromes)
If you have any doubts, ask your doctor or pharmacist for advice.
Warnings and precautions Talk to your doctor or pharmacist before taking Amifampridine SERB.
Tell your doctor if you have:
Asthma A history of fits (convulsions) Kidney problems Liver problems
Your doctor will monitor carefully how Amifampridine SERB works for you and may need to change the dose of the medicines you take. Your doctor will also monitor your heart at the start of your treatment and also every year thereafter.
If you have LEMS but do not have cancer, your doctor will make a thorough assessment of the potential risk of cancer with Amifampridine SERB before commencing treatment.
Tell any physician you consult that you are using Amifampridine SERB.
Stop the treatment and immediately consult your doctor in the event of: Fits (convulsions) Asthma
Other medicines and Amifampridine SERB Tell your doctor if you are taking, have recently taken or might take any other medicines.
Some medicines may interact with Amifampridine SERB when taken together. The following medicines must not be combined with Amifampridine SERB:
Medicines that may change the electrical activity of your heart (QT-interval prolongation - detectable in the electrocardiogram) e.g., sultopride, disopyramide, cisapride, domperidone, rifampicin, and ketoconazole (see Do not take Amifampridine SERB )
It is especially important to talk to your doctor if you are taking one of the following medicines or plan to start taking the following medicines: Medicines for malaria (e.g. halofantrine and mefloquine) Tramadol (a painkiller) Antidepressants - tricyclic antidepressants (e.g. clomipramine, amoxapine), selective serotonin reuptake inhibitors (e.g. citalopram, dapoxetine) and atypical antidepressants (e.g. buproprion) Medicines for mental problems (e.g. haloperidol, carbamazapine, chlorpromazine, clozapine) Medicines to treat Parkinson's disease - anticholinergics (e.g. trihexylphenidyl, mesylate), MAO-B inhibitors (e.g. selegiline, deprenyl), COMT inhibitors (e.g. entacapone) Medicines to treat allergies - antihistamines (e.g. terfenadine, astemizole, cimetidine) Medicines to relax your muscles - (e.g. mivacurium, pipercurium, suxamethonium) Sedatives (e.g. barbiturates)
Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Amifampridine SERB should not be used if you are pregnant. You must use effective contraception throughout the treatment. If you discover that you are pregnant during the treatment, inform your doctor immediately.
It is not known whether Amifampridine SERB is excreted in human breast milk. You and your doctor should discuss the risks and benefits of continuing to take Amifampridine SERB while breastfeeding.
Driving and using machines This medicine may cause drowsiness, dizziness, fits (convulsions) and blurred vision, which may affect your ability to drive or use machines. Do not drive or operate machines if you experience these side effects.
Always take this medicine exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.
The dose you should take is established by your doctor based on the intensity of your symptoms and certain genetic factors. This dose suits you only.
The starting dose is 5 mg amifampridine (half a tablet) three times daily (i.e. 15 mg per day). Your doctor may increase this dose slowly first to 5 mg (half a tablet) four times daily (i.e. 20 mg per day). Then your doctor may continue to increase your total daily dose adding 5 mg (half a tablet) per day, every 4 or 5 days.
The maximum recommended dose is 60 mg per day (i.e. a total of six tablets to be taken at intervals during the day). Total daily doses above 20 mg should be divided into two to four separate doses. No single dose should exceed 20 mg (two tablets).
The tablets have a score-line to allow them to be broken in half. The tablets should be swallowed with some water and are to be taken with food.
Patients with liver/kidney problems Amifampridine SERB should be used with caution in patients with liver or kidney problems. A starting dose of 5 mg (half tablet) Amifampridine SERB daily is recommended in patients with moderate or severe liver or kidney problems. For patients with mild liver or kidney problems a starting dose of 10 mg (5 mg twice a day) Amifampridine SERB daily is recommended. For these patients the dose of Amifampridine SERB should be increased more slowly than in those without liver or kidney problems with doses increased in 5 mg increments every 7 days. If any side effects occur, please consult your doctor as you may need to stop increasing the dose.
If you take more Amifampridine SERB than you should If you take more Amifampridine SERB than you should have, you may suffer from vomiting or a stomach ache. If you experience any of these symptoms, you should contact your doctor or pharmacist immediately.
If you forget to take Amifampridine SERB If you forget to take Amifampridine SERB, do not take a double dose to make up for the dose you have forgotten but continue to take your treatment as prescribed by your doctor.
If you stop taking Amifampridine SERB If the treatment is stopped, you may experience symptoms such as tiredness, slow reflexes and constipation. Do not stop treatment without consulting your doctor.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Stop the treatment and immediately consult your doctor in the event of: Fits (convulsions) Asthma
Very common side effects which may affect more than 1 in 10 people are: Tingling and numbness around the mouth and extremities (such as feet and hands) Reduced sense of touch or sensation Nausea Dizziness Increase sweating, cold sweat
Common side effects which may affect up to 1 in 10 people are: Stomach ache
Cold hands and feet
Other side effects are: The intensity and incidence of most side effects depends on the dose you are taking. The following side effects have also been reported (frequencies cannot be estimated from the available data): Raynaud's syndrome (circulation disorder affecting the fingers and toes) Diarrhoea Fits (convulsions) Cough, excessive or viscous mucus in the breathing passage, asthma attack in asthmatic patients or patients with a history of asthma Blurred vision Heart rhythm disorders, fast or irregular heartbeats (palpitations) Weakness, tiredness, headache
Anxiety, sleep disorders, drowsiness Chorea (movement disorder), myoclonia (muscle spasm or twitching) Increase in certain liver enzymes (transaminases) seen on blood tests
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and on the blister after EXP. The expiry date refers to the last day of that month.
This medicinal product does not require any special temperature storage conditions. Store in the original package, in order to protect from light.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
What Amifampridine SERB contains The active substance is amifampridine. Each tablet contains amifampridine phosphate equivalent to 10 mg of amifampridine. The other ingredients are microcrystalline cellulose, anhydrous colloidal silica and calcium stearate.
What Amifampridine SERB looks like and contents of the pack White, round tablet, flat-faced on one side and scored on the other side. The tablets can be divided into equal doses. 10 x 1 tablets in aluminium-PVC/PVDC perforated unit dose blisters . Pack-sizes of 90 x 1 tablets, 100 x 1 tablets and 120 x 1 tablets. Not all pack sizes may be marketed.
Marketing Authorisation Holder SERB S.A.
Avenue Louise 1050 Bruxelles Belgium
Manufacturers EXCELLA GmbH & Co KG N rnberger Strasse 90537 Feucht
Germany
SERB S.A.
Avenue Louise 1050 Bruxelles Belgium
This leaflet was last revised in
Amifampridine SERB contains the same active substance and works in the same way as a reference medicine already authorised in the EU. The reference medicine for Amifampridine SERB has been authorised under exceptional circumstances . This means that because of the rarity of this disease it has been impossible to get complete information on the reference medicine. The European Medicines Agency will review any new information on the reference medicine every year and any updates for the reference medicine will also be included as appropriate in the information for Amifampridine SERB, such as this leaflet
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-eea75696c0638bfef12b52e191d0d8ce
Resource Composition:
Generated Narrative: Composition composition-en-eea75696c0638bfef12b52e191d0d8ce
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/22/1646/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - amifampridine
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mpeea75696c0638bfef12b52e191d0d8ce
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mpeea75696c0638bfef12b52e191d0d8ce
identifier:
http://ema.europa.eu/identifier
/EU/1/22/1646/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Amifampridine SERB 10 mg tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en